Drug Profile
Insulin lispro biphasic biosimilar - Geropharm
Alternative Names: Insulin lispro biphasic 25; Insulin Lispro Mix 25Latest Information Update: 21 Apr 2022
Price :
$50
*
At a glance
- Originator GEROPHARM
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 21 Apr 2022 No development reported - Phase-III for Type 2 diabetes mellitus in Russia (SC) (Geropharm pipeline, April 2022)
- 18 Apr 2019 Geropharm completes a phase III trial in Type 2 diabetes mellitus in Russia (NCT04023344)
- 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Type-1 diabetes mellitus in Russia (SC)